These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30389433)

  • 21. Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.
    Yu S; Wang M; Zhang H; Guo X; Qin R
    J Cell Mol Med; 2024 Jun; 28(12):e18444. PubMed ID: 38924205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
    Yu S; Wang M; Zhang H; Guo X; Qin R
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
    Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
    Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
    Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
    Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway.
    Ma H; Kong L; Liu L; Du Y; Zhu X; Wang J; Zhao W
    Mol Carcinog; 2024 Jul; 63(7):1221-1234. PubMed ID: 38517039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
    ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.
    Johnson JL; Dia VP; Wallig M; Gonzalez de Mejia E
    Pancreas; 2015 Jan; 44(1):144-51. PubMed ID: 25237909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.
    Zhao Y; Tu MJ; Wang WP; Qiu JX; Yu AX; Yu AM
    Sci Rep; 2016 May; 6():26611. PubMed ID: 27216562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
    Luo D; Digiovanni MG; Wei R; Lacomb JF; Williams JL; Rigas B; Mackenzie GG
    Carcinogenesis; 2020 Jul; 41(7):927-939. PubMed ID: 31584613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
    Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
    Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
    [No Abstract]   [Full Text] [Related]  

  • 33. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
    Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
    Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
    Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.